TheraRadar
← Back
Data updated: Jul 17, 2026

Novo Nordisk

NVO Big Pharma
MetabolicImmunologyCardiovascular Execution: Excellent

Danish pharma dominating diabetes and obesity markets with Ozempic, Wegovy, and insulin portfolio. World leader in GLP-1 therapies.

$35.7B
Revenue (2024)
$420.0B
Market Cap
-
Trials
4
New Drugs (2yr)
Modality:
8 Small Molecules 21 Biologics

FDA Novel Drug Designations

(2017-2024)
4 Novel 1 First-in-Class 2 Orphan 1 Breakthrough 1 Priority Review
See 4 novel approvals →
2024 ALHEMO (CONCIZUMAB) Orphan · Priority Review
2023 RIVFLOZA (NEDOSIRAN SODIUM) First-in-Class · Orphan · Breakthrough
2020 SOGROYA (SOMAPACITAN-BECO)
2017 OZEMPIC (SEMAGLUTIDE)

Novo Nordisk at a Glance

  • Strong track record with 84% execution quality across 709 trials
  • Fast trial execution (12 months median completion)

Upcoming FDA Decisions

Full Calendar →
Oct 18, 2026 — CagriSema (cagrilintide + semaglutide)

Novo Nordisk's Recent FDA Approvals

Novo Nordisk secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

AWIQLI FLEXTOUCH BLA
2026-03-26
insulin icodec
1 INDICATIONS AND USAGE Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Awiqli is a long-acting human insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 )
WEGOVY NDA
2025-12-22
semaglutide
1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity. o Adults with overweight in the presence of at least one weight-related comorbid condition. • For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies ( 14.4 )] . Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) event
ALHEMO BLA
2025-07-31
concizumab
Hemophilia A
ALHEMO BLA
2024-12-20
concizumab-mtci
Hemophilia A

Novo Nordisk's Therapeutic Areas

Novo Nordisk's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Immunology, across 21 biologic and 8 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 93%
12 drugs Phase 3: 199 Phase 2: 39 Phase 1: 300
Immunology 3%
0 drugs Phase 3: 2 Phase 2: 8 Phase 1: 11
Cardiovascular 2%
0 drugs Phase 3: 4 Phase 2: 3 Phase 1: 8
Infectious Disease 1%
0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 5
Neurology 1%
0 drugs Phase 3: 3 Phase 2: 1

Novo Nordisk's Top Competitors

Novo Nordisk's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Sanofi big-pharma
Metabolic, Infectious Disease, Immunology, Cardiovascular
Pfizer big-pharma
Infectious Disease, Immunology, Neurology
Merck big-pharma
Infectious Disease, Metabolic, Cardiovascular
AbbVie big-pharma
Immunology, Infectious Disease, Neurology
LEDERLE big-pharma
Infectious Disease, Immunology, Cardiovascular, Neurology

Novo Nordisk Pipeline Snapshot

Novo Nordisk has 587 active clinical programs from ClinicalTrials.gov — 209 Phase 3, 54 Phase 2 and 324 Phase 1.

209
Phase 3
54
Phase 2
324
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Ziltivekimab
Heart Failure
Estimated · fresh NCT06200207
Q4 2026
Ziltivekimab
Cardiovascular Risk
Estimated · fresh NCT06118281
Q4 2026
Semaglutide
Diabetes Mellitus, Type 2
Estimated · fresh NCT03811561
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OZEMPIC leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 204/246 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges